Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three ...

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in ...

To begin with, this trial recruited 12 people with mantle cell lymphoma that had come back after treatment. They all had ofatumumab through a drip into a vein, once a week for up to 5 weeks. When the ...

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a ...

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell ...

Among patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), Columvi (glofitamab) plus chemotherapy with gemcitabine and oxaliplatin (GemOx) demonstrated enhanced survival outcomes ...

Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...

Genmab A/S today announced new results from the Phase 1 b/2 EPCORE ® NHL-2 trial Arm 10, evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination ...

Doctors discovered it was lymphoma. As the lump in Makaila Chenier's neck grew, it became difficult for her to breathe. That's when she knew she needed to see a doctor.